Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
The DOI matches its Crossref record; 131 of the 134 references it cites were found in a registry or an index.
Abstract
Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are identified as safe, well-tolerated rapid-acting antidepressants in adults with treatment-resistant depression, and also mitigate measures of suicidality. Psilocybin is a naturally occurring psychoactive alkaloid and non-selective agonist at many serotonin receptors, especially at serotonin 5-HT 2A receptors, and is found in the Psilocybe genus of mushrooms. Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. The pharmacodynamic mechanisms mediating the antidepressant and psychedelic effects of psilocybin are currently unknown but are thought to involve the modulation of the serotonergic system, primarily through agonism at the 5-HT 2A receptors and downstream changes in gene expression. It is also established that indirect effects on dopaminergic and glutamatergic systems are contributory, as well as effects at other lower affinity targets. Along with the direct effects on neurochemical systems, psilocybin alters neural circuitry and key brain regions previously implicated in depression, including the default mode network and amygdala. The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psychedelic and putative antidepressant properties of psiloc…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite neuroplasticity phenomena mainly occurring in the prefrontal cortex, amygdala, and hippocampus, 66”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [66]
In the citing paper
“Psilocybin (4-phosphryloxy-N,N-dimethyltryptamine) is a serotonergic classic psychedelic (19–25) that has been examined in combination with psychological support as a promising treatment option in clinical trials for various disorders (26–28).”
In the citing paper
“As with SSRIs, their enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [129]
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“Psilocybin is a naturally occurring psychedelic found in the Psilocybe genus of mushrooms [30].”
BackgroundHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · cited 1×
“, analyses of secondary outcomes were not corrected for multiple comparisons), the relative antidepressant efficacy of psilocybin remains incompletely understood [32].”
ResultPatterson, S. L., Abel, T., Deuel, T. A. S., Martin, K. C., Rose, J. C., & Kandel, E. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80140-3 · Cited by 1,233
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“In vitro and in vivo studies have also demonstrated increased neuritogenesis and spinogenesis in the PFC upon 5-HT2AR agonism [100].”
BackgroundNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“Ultimately, complex alterations in connectivity between neural networks occur, allowing new connections in the brain to be formed; this phenomenon has been referred to as a ‘pharmaco-physiological interaction’ [93].”
BackgroundDuman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026 · cited 1×
“It is important to note, however, that these recent studies stand in contrast to the widely accepted theory of glutamatergic activity, in which neuronal atrophy in the brain reward circuitry results in decreased glutamatergic synaptic excitation [19].”
ResultPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 2×
“other 5-HT2 receptors, such as the 5-HT2C receptors, did not completely attenuate psilocybin-induced hallucinatory effects [42, 43].”
BackgroundCole, A. J., Saffen, D. W., Baraban, J. M., & Worley, P. F. (1989) · Nature · doi:10.1038/340474a0 · Cited by 1,009 · cited 1×
“, LTP), suggesting that psilocybin may activate key neuroplastic pathways underlying its putative antidepressant effects [53, 54].”
BackgroundBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Glutamatergic modulation of NMDA receptors and increased BDNF are the predominant proposed antidepressant mechanisms of ketamine, thus suggesting the parallel involvement of this mechanism in mediating antidepressant effects of psilocybin [60].”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 2×
“The foregoing gene expression findings may present key mediators in 5-HT2AR agonist-induced hallucination, such that egr-1 and egr-2 expression may be necessary for the induction of hallucinogenic effects, whereas c-fos expression corresponds only to neuronal activity at the 5-HT2ARs and is not sufficient to modify do…”
BackgroundHamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071105 · Cited by 866
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808 · cited 1×
“However, an open-label study on patients with TRD reported contrasting findings, revealing that psilocybin increased right amygdala activity in response to fearful and happy faces at 1 day post-treatment [98].”
BackgroundIdentification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803 · cited 1×
“Additionally, administration of DOI in mGlu2-knockout mice over-expressing a chimeric mGlu2 construct which cannot be complexed with 5-HT2ARs in the frontal cortex did not restore head-twitch behavior [50, 51].”
BackgroundEssential Role for TrkB Receptors in Hippocampus-Mediated Learning
Minichiello, L., Korte, M., Wolfer, D., Kühn, R., Unsicker, K., Cestari, V., Rossi-Arnaud, C., Lipp, H.-P., Bonhoeffer, T., & Klein, R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80853-3 · Cited by 799
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789 · cited 1×
“Multiple studies have shown that treatment with proinflammatory cytokines, including TNF-α and IL-6, induce depression-like behavior assessed via forced swim tests [69, 70].”
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731 · cited 2×
“The foregoing findings are proffered as explanatory for the antidepressant properties of ketamine, an NMDA antagonist proven effective for the rapid-onset treatment of TRD and MDD with suicidality [8].”
BackgroundSelf-citationThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 3×
“In addition, re-expression of 5-HT2ARs in cortical pyramidal neurons was able to successfully restore hallucinogen-induced head twitching [44, 45].”
BackgroundKappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659 · cited 1×
“Moreover, IL-6 and TNF-α antagonists have previously been proven efficacious in treating depressive symptoms [73].”
BackgroundEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631 · cited 2×
“The actions of psilocybin on the 5-HT2ARs and the possible involvement of these receptors in mediating the hallucinogenic effects of psilocybin were first reported by Glennon et al. in 1984, who noted a significant correlation between the binding affinities for 5-HT2 receptors and the dose that produced 50% of the max…”
BackgroundInflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Self-citationA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587
Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Depression, rumination and the default network
Berman, M. G., Peltier, S., Nee, D. E., Kross, E., Deldin, P. J., & Jonides, J. (2011) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsq080 · Cited by 568 · cited 1×
“Currently accepted neural models of MDD are characterized by overactivity of the amygdala due to altered connectivity in the default mode network (DMN), particularly in the medial prefrontal cortex (mPFC) [45, 91, 92].”
BackgroundZhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538
Zhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., & Sheehan, J. J. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13699 · Cited by 523 · cited 1×
“Much of the socioeconomic burden associated with MDD is attributable to treatment-resistant depression (TRD), characterized by failure to achieve full remission following treatment with two conventional antidepressants [2, 3].”
BackgroundInfluentialMechanism of TrkB-Mediated Hippocampal Long-Term Potentiation
Minichiello, L., Calella, A. M., Medina, D. L., Bonhoeffer, T., Klein, R., & Korte, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00942-x · Cited by 506 · cited 2×
“Activation of the Ras/MAPK and PI3K signal transduction cascades ultimately increases intracellular calcium levels, resulting in further activation of important transcription factors involved in mediating changes to synaptic gene expression, such as cAMP response element binding protein (CREB) [105, 107].”
BackgroundThe pharmacology of psilocybin
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002) · Addiction Biology · doi:10.1080/1355621021000005937 · Cited by 465 · cited 1×
“In addition, psilocybin has a short acute window of 2–6 h, which contributes to more manageable and inexpensive clinical trials, differing greatly from mescaline and LSD with acute windows of 6–8 h and 8–20 h, respectively [27, 28].”
BackgroundThe Role of BDNF on Neural Plasticity in Depression
Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., Yu, S., & Liu, H. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00082 · Cited by 435 · cited 3×
“Current models suggest that BDNF increases neuroplasticity by promoting neuronal proliferation and survival [105].”
BackgroundCortical 5-HT 2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice
Weisstaub, N. V., Zhou, M., Lira, A., Lambe, E., González-Maeso, J., Hornung, J.-P., Sibille, E., Underwood, M., Itohara, S., Dauer, W. T., et al. (2006) · Science · doi:10.1126/science.1123432 · Cited by 425 · cited 1×
“, rescue experiments) restored anxiety symptoms [57].”
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 1×
“Much of the socioeconomic burden associated with MDD is attributable to treatment-resistant depression (TRD), characterized by failure to achieve full remission following treatment with two conventional antidepressants [2, 3].”
BackgroundInfluentialSelf-citationMultiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 411 · cited 4×
“It also has weak affinity for other 5-HT receptors, including 5-HT3/5/6/7 and imidazoline 1 receptors [41, 79].”
BackgroundInfluentialRole of Interleukin-6 in Depressive Disorder
Ting, E. Y.-C., Yang, A. C., & Tsai, S.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062194 · Cited by 385
The role of serotonin 5-HT2A receptors in memory and cognition
Zhang, G., & Stackman, R. W. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00225 · Cited by 382 · cited 1×
“It has been proposed that 5-HT2AR activation increases cortical neural plasticity [100, 104].”
BackgroundHesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378 · cited 1×
“In addition, the role of the psychedelic experience in mediating antidepressant effects is unknown [34, 35].”
BackgroundThe Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders
Duclot, F., & Kabbaj, M. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00035 · Cited by 363 · cited 2×
“Expression of egr-1 has previously been implicated in neuronal plasticity [53].”
BackgroundKishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 4×
“In recognition of the inadequacy of conventional first-line antidepressants and the unmet needs of individuals with TRD, along with the recent US Food and Drug Administration and European Medicines Agency approval of esketamine [8], * Roger S. McIntyre roger.mcintyre@uhn.ca Extended author information available on the…”
BackgroundInfluentialKometer, M., Schmidt, A., Jancke, L., & Vollenweider, F. X. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3007-12.2013 · Cited by 355 · cited 2×
“Although the visual hallucinatory effects of psilocybin are largely associated with increased activity in 5-HT2ARs of the visual cortex, previous studies have suggested that overexpression of 5-HT2ARs is present in patients with MDD, with expression correlating positively to the severity and duration of depression [39…”
BackgroundA systems model of altered consciousness: integrating natural and drug-induced psychoses
Vollenweider, F. X., & Geyer, M. A. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00646-3 · Cited by 343 · cited 1×
“, loss of physical integrity, pronounced anxiety, emotional withdrawal) [40, 41].”
BackgroundStructural and synaptic plasticity in stress-related disorders
Christoffel, D. J., Golden, S. A., & Russo, S. J. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.044 · Cited by 334 · cited 11×
“Studies attribute the increase in activity to a glutamate-dependent interaction; early studies have implicated activation of presynaptic 5-HT2ARs on glutamatergic thalamocortical afferents projecting to the PFC [83].”
BackgroundInfluentialRecent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · cited 1×
“In addition, psilocybin has a short acute window of 2–6 h, which contributes to more manageable and inexpensive clinical trials, differing greatly from mescaline and LSD with acute windows of 6–8 h and 8–20 h, respectively [27, 28].”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways
López-Giménez, J. F., & González-Maeso, J. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_478 · Cited by 299 · cited 2×
“These Gi/o proteins are further coupled to metabotropic glutamate receptor 2 (mGlu2) receptors, ultimately forming a co-expressed 5-HT2A/mGlu2 complex [47].”
BackgroundKometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.005 · Cited by 298
González-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297 · cited 1×
“This difference in G protein activation and specific signaling pathways between 5-HT2AR hallucinogens and non-hallucinogens is referred to as the ‘agonist trafficking of receptor signaling theory’ [52].”
BackgroundZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289 · cited 1×
“demonstrated that lipopolysaccharide-induced inflammation in mice resulted in a depression-like phenotype due to alterations in the BDNF-TrkB signaling pathway within the CA3 and dentate gyrus regions of the hippocampus as well as in the PFC and nucleus accumbens [113].”
BackgroundPsilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276 · cited 6×
“Other studies have implicated the necessity of D2 antagonism for reducing psychotic effects independently of 5-HT2AR activity [41].”
BackgroundInfluentialA role for BDNF in the late-phase of hippocampal long-term potentiation
Korte, M., Kang, H., Bonhoeffer, T., & Schuman, E. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00035-5 · Cited by 268
Mason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258
Classical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · cited 2×
“with a single dose of ayahuasca; however, antidepressant effects of ayahuasca cannot be attributed to 5-HT2AR agonism alone as it also inhibits MAO activity [116, 117].”
BackgroundChui, R., & Dorovini-Zis, K. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-1 · Cited by 250
Neuronal plasticity and antidepressant actions
Castrén, E., & Hen, R. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.12.010 · Cited by 243
Effects of psilocybin on time perception and temporal control of behaviour in humans
Wittmann, M., Carter, O., Hasler, F., Cahn, B. R., Grimberg, U., Spring, P., Hell, D., Flohr, H., & Vollenweider, F. X. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106065859 · Cited by 239
Moreno, J. L., Holloway, T., Albizu, L., Sealfon, S. C., & González-Maeso, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.01.046 · Cited by 234 · cited 1×
“In mGlu2-knockout mice, administration of the serotonergic hallucinogens 4-iodo-2,5-dimethoxyphenyl-isopropylamine (DOI) and LSD did not induce head-twitch behavior [49].”
BackgroundQuednow, B. B., Kometer, M., Geyer, M. A., & Vollenweider, F. X. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.228 · Cited by 230 · cited 1×
“other 5-HT2 receptors, such as the 5-HT2C receptors, did not completely attenuate psilocybin-induced hallucinatory effects [42, 43].”
BackgroundCarter, O. L., Burr, D. C., Pettigrew, J. D., Wallis, G. M., Hasler, F., & Vollenweider, F. X. (2005) · Journal of Cognitive Neuroscience · doi:10.1162/089892905774597191 · Cited by 230
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · cited 11×
“Studies attribute the increase in activity to a glutamate-dependent interaction; early studies have implicated activation of presynaptic 5-HT2ARs on glutamatergic thalamocortical afferents projecting to the PFC [83].”
BackgroundInfluentialAgonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Schmid, C. L., Raehal, K. M., & Bohn, L. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708862105 · Cited by 229 · cited 1×
“In comparison, the hallucinogenic 5-HT 2AR agonist DOI induces head twitching independent of β-arrestin-2 interactions [55, 56].”
BackgroundThe experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis
Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112749 · Cited by 229
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance
Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224 · cited 3×
“These findings may suggest an indirect role of the dopaminergic system in eliciting hallucinations, as interactions between serotonergic and dopaminergic systems have been established [33].”
BackgroundInfluential5-HT2A and 5-HT2C receptors and their atypical regulation properties
Van Oekelen, D., Luyten, W. H. M. L., & Leysen, J. E. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00141-3 · Cited by 224 · cited 1×
“Collectively, these findings suggest a possible role for 5-HT2AR downregulation and desensitization in mitigating depressive and anxious symptoms [58].”
BackgroundPuig, M. V. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.8.870 · Cited by 222 · cited 11×
“Studies attribute the increase in activity to a glutamate-dependent interaction; early studies have implicated activation of presynaptic 5-HT2ARs on glutamatergic thalamocortical afferents projecting to the PFC [83].”
BackgroundInfluentialAlbert, P. R., Benkelfat, C., & Descarries, L. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0190 · Cited by 218 · cited 1×
“Although the pathophysiology and neurobiology of depression are not completely understood, the traditional ‘serotonin hypothesis’ of MDD asserts that a deficit of central serotonin subserves depressive symptoms [13].”
BackgroundMertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208 · cited 2×
“The decreased connectivity, however, was associated with the occurrence of increased activity in the amygdala in response to fearful and neutral faces [37].”
BackgroundKetamine and rapid-acting antidepressants: a new era in the battle against depression and suicide
Duman, R. S. (2018) · F1000Research · doi:10.12688/f1000research.14344.1 · Cited by 207
Hibicke, M., Landry, A. N., Kramer, H. M., Talman, Z. K., & Nichols, C. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00493 · Cited by 205 · cited 1×
“In addition, the role of the psychedelic experience in mediating antidepressant effects is unknown [34, 35].”
BackgroundDefault mode network dissociation in depressive and anxiety states
Coutinho, J. F., Fernandesl, S. V., Soares, J. M., Maia, L., Gonçalves, Ó. F., & Sampaio, A. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9375-7 · Cited by 203 · cited 1×
“Currently accepted neural models of MDD are characterized by overactivity of the amygdala due to altered connectivity in the default mode network (DMN), particularly in the medial prefrontal cortex (mPFC) [45, 91, 92].”
BackgroundAn update on regional brain volume differences associated with mood disorders
Campbell, S., & MacQueen, G. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000194371.47685.f2 · Cited by 198
Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo
Nau, F., Yu, B., Martin, D., & Nichols, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075426 · Cited by 198 · cited 1×
“Murine studies have shown that agonism at the 5-HT2AR by DOI results in downstream inhibition of TNF-α and subsequent inhibition of IL-6 release [74].”
BackgroundEffect of Psilocybin on Empathy and Moral Decision-Making
Pokorny, T., Preller, K. H., Kometer, M., Dziobek, I., & Vollenweider, F. X. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx047 · Cited by 197 · cited 1×
“normal electroencephalographic changes that occurred upon psilocybin administration [79, 90].”
BackgroundMICHELSEN, K., PRICKAERTS, J., & STEINBUSCH, H. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00912-6 · Cited by 196
Szabo, A., Kovacs, A., Frecska, E., & Rajnavolgyi, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106533 · Cited by 191
Vollenweider, F. X., Csomor, P. A., Knappe, B., Geyer, M. A., & Quednow, B. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301324 · Cited by 190
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Mechanisms of tumor necrosis factor-α-induced interleukin-6 synthesis in glioma cells
Tanabe, K., Matsushima-Nishiwaki, R., Yamaguchi, S., Iida, H., Dohi, S., & Kozawa, O. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-16 · Cited by 177 · cited 3×
“Such findings correlate with the accepted mechanism of TNF-α in inducing IL-6 synthesis through phosphorylation of NFκB and activation of the mitogenactivated protein kinase (MAPK) pathway via phosphorylation of p38 MAPK [67, 68].”
BackgroundSchmid, C. L., & Bohn, L. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1665-10.2010 · Cited by 175 · cited 1×
“In comparison, the hallucinogenic 5-HT 2AR agonist DOI induces head twitching independent of β-arrestin-2 interactions [55, 56].”
BackgroundTang, S., Lu, L., Zhang, L., Hu, X., Bu, X., Li, H., Hu, X., Gao, Y., Zeng, Z., Gong, Q., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.010 · Cited by 175
Effects of interleukin-1 and endotoxin in the forced swim and tail suspension tests in mice
DUNN, A., & SWIERGIEL, A. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.04.019 · Cited by 169 · cited 1×
“Multiple studies have shown that treatment with proinflammatory cytokines, including TNF-α and IL-6, induce depression-like behavior assessed via forced swim tests [69, 70].”
MethodGewirtz, J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00136-6 · Cited by 164 · cited 1×
“Similarly, administration of DOI in the presence of LY354740 was not able to restore head-twitch behavior in mice whereas administration of DOI with the mGlu2/3 antagonist LY341495 increased head-twitch behavior [85, 86].”
BackgroundMarek, G. J., Wright, R. A., Gewirtz, J. C., & Schoepp, D. D. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00199-3 · Cited by 158 · cited 11×
“Studies attribute the increase in activity to a glutamate-dependent interaction; early studies have implicated activation of presynaptic 5-HT2ARs on glutamatergic thalamocortical afferents projecting to the PFC [83].”
BackgroundInfluentialAnimal Models of Serotonergic Psychedelics
Hanks, J. B., & González-Maeso, J. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn300138m · Cited by 156 · cited 1×
“, locomotor responses, anxiolytic effects, alterations in time perception) were not investigated [46].”
BackgroundTreatment-Resistant Depression in Primary Care across Canada
Rizvi, S. J., Grima, E., Tan, M., Rotzinger, S., Lin, P., McIntyre, R. S., & Kennedy, S. H. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900702 · Cited by 144 · cited 1×
“In 2013, TRD was reportedly responsible for a 40–50% increase in direct and indirect medical care costs when compared with treatment-responsive depression [4].”
BackgroundSelf-citationDARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 141 · cited 3×
“0 nM), specifically at 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) and median raphe nucleus [87, 88].”
BackgroundMoreno, J. L., Muguruza, C., Umali, A., Mortillo, S., Holloway, T., Pilar-Cuéllar, F., Mocci, G., Seto, J., Callado, L. F., Neve, R. L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.413161 · Cited by 140 · cited 1×
“Additionally, administration of DOI in mGlu2-knockout mice over-expressing a chimeric mGlu2 construct which cannot be complexed with 5-HT2ARs in the frontal cortex did not restore head-twitch behavior [50, 51].”
BackgroundMolecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133 · cited 1×
“Although there is no well-characterized time frame of therapeutic action for RAADs, these treatments show therapeutic efficacy within a few days to a week [9].”
BackgroundThe TNF-α System: Functional Aspects in Depression, Narcolepsy and Psychopharmacology
Berthold-Losleben, M., & Himmerich, H. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777238 · Cited by 119
Carter, O. L., Pettigrew, J. D., Hasler, F., Wallis, G. M., Liu, G. B., Hell, D., & Vollenweider, F. X. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300621 · Cited by 118
De Cesaris, P., Starace, D., Riccioli, A., Padula, F., Filippini, A., & Ziparo, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7566 · Cited by 116 · cited 3×
“Such findings correlate with the accepted mechanism of TNF-α in inducing IL-6 synthesis through phosphorylation of NFκB and activation of the mitogenactivated protein kinase (MAPK) pathway via phosphorylation of p38 MAPK [67, 68].”
BackgroundEffects of varied doses of psilocybin on time interval reproduction in human subjects
Wackermann, J., Wittmann, M., Hasler, F., & Vollenweider, F. X. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.006 · Cited by 111
(1975) · PubMed · Cited by 101
Gruart, A., Sciarretta, C., Valenzuela-Harrington, M., Delgado-García, J. M., & Minichiello, L. (2007) · Learning & Memory · doi:10.1101/lm.428307 · Cited by 97
Depression, traumatic stress and interleukin-6
Bob, P., Raboch, J., Maes, M., Susta, M., Pavlat, J., Jasova, D., Vevera, J., Uhrova, J., Benakova, H., & Zima, T. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.03.017 · Cited by 97
Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K., & Stamatakis, E. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117049 · Cited by 96
Müller, N., Myint, A.-M., & Schwarz, M. J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.3/nmueller · Cited by 93
Luo, Y., He, H., Zhang, M., Huang, X., & Fan, N. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.07.027 · Cited by 88 · cited 1×
“In addition, other studies have indicated a positive correlation between TNF-α and IL-6 levels and depressive scores [71, 72].”
BackgroundDodd, S., Bauer, M., Carvalho, A. F., Eyre, H., Fava, M., Kasper, S., Kennedy, S. H., Khoo, J.-P., Lopez Jaramillo, C., Malhi, G. S., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1851052 · Cited by 88
Self-citationAltered Serum Levels of TNF-α, IL-6, and IL-18 in Depressive Disorder Patients
Fan, N., Luo, Y., Ou, Y., & He, H. (2017) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2588 · Cited by 85 · cited 1×
“In addition, other studies have indicated a positive correlation between TNF-α and IL-6 levels and depressive scores [71, 72].”
BackgroundGouzoulis-Mayfrank, E., Heekeren, K., Thelen, B., Lindenblatt, H., Kovar, K. A., Sass, H., & Geyer, M. A. (1998) · Behavioural Pharmacology · doi:10.1097/00008877-199811000-00011 · Cited by 80
Clinical potential of psilocybin as a treatment for mental health conditions
Daniel, J., & Haberman, M. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.024 · Cited by 79 · cited 1×
“Activation of 5-HT2ARs within the thalamus and mPFC may also decrease thalamic activity, leading to decreased consciousness, alertness, and sensory signals, which contribute to the psychedelic experience [94].”
BackgroundSerafini, G., Pompili, M., Innamorati, M., Dwivedi, Y., Brahmachari, G., & Girardi, P. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990293 · Cited by 78
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
An update on NMDA antagonists in depression
Pochwat, B., Nowak, G., & Szewczyk, B. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1643237 · Cited by 70
Blunted amygdala activity is associated with depression severity in treatment-resistant depression
Ferri, J., Eisendrath, S. J., Fryer, S. L., Gillung, E., Roach, B. J., & Mathalon, D. H. (2017) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-017-0544-6 · Cited by 67
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
NMDA Receptor Antagonists for Treatment of Depression
Ates-Alagoz, Z., & Adejare, A. (2013) · Pharmaceuticals · doi:10.3390/ph6040480 · Cited by 65
The emerging role of psilocybin and MDMA in the treatment of mental illness
Gill, H., Gill, B., Chen-Li, D., El-Halabi, S., Rodrigues, N. B., Cha, D. S., Lipsitz, O., Lee, Y., Rosenblat, J. D., Majeed, A., et al. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1826931 · Cited by 61 · cited 17×
“The preceding result suggests possible downstream expression of BDNF following the binding of psilocybin, ultimately leading to downregulation of 5-HT2ARs [59].”
BackgroundResultInfluentialSelf-citationBernasconi, F., Schmidt, A., Pokorny, T., Kometer, M., Seifritz, E., & Vollenweider, F. X. (2014) · Cerebral Cortex · doi:10.1093/cercor/bht178 · Cited by 60
Fava, M., Dirks, B., Freeman, M. P., Papakostas, G. I., Shelton, R. C., Thase, M. E., Trivedi, M. H., Liu, K., & Stankovic, S. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12928 · Cited by 50 · cited 19×
“Numerous functional magnetic resonance imaging studies have presented findings consistent with these models and suggest psilocybin induces decreased activity in brain regions and networks associated with MDD, including the amygdala and DMN, which may ultimately underlie its therapeutic effects.”
BackgroundInfluentialThe dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Peripheral inflammatory biomarkers define biotypes of bipolar depression
Lee, Y., Mansur, R. B., Brietzke, E., Kapogiannis, D., Delgado-Peraza, F., Boutilier, J. J., Chan, T. C. Y., Carmona, N. E., Rosenblat, J. D., Lee, J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01051-y · Cited by 48
Self-citationHallucinogen actions on human brain revealed
Lee, H.-M., & Roth, B. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121358109 · Cited by 46 · cited 2×
“In addition, re-expression of 5-HT2ARs in cortical pyramidal neurons was able to successfully restore hallucinogen-induced head twitching [44, 45].”
BackgroundRole of psilocybin in the treatment of depression
Mahapatra, A., & Gupta, R. G. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316676092 · Cited by 44 · cited 5×
“5-HT2ARs are highly expressed in the visual cortex, thus, receptor activity in visual cortical neurons may be sufficient to mediate psychedelic effects, specifically the propensity for visual hallucinations associated with psilocybin [25].”
BackgroundInfluentialImmunological Consequences of In Vitro Exposure to Lysergic Acid Diethylamide (LSD)
House, R. V., Thomas, P. T., & Bhargava, H. N. (1994) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923979409029898 · Cited by 43
Cruz, M. P. (2017) · PubMed · Cited by 39
Pałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36 · cited 1×
“Other RAADs such as ketamine also exhibit similar modulatory effects on the glutamatergic system, including but not limited to, mGlu2/3 antagonism [84].”
BackgroundSalloum, N. C., Fava, M., Hock, R. S., Freeman, M. P., Flynn, M., Hoeppner, B., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.09.017 · Cited by 34 · cited 4×
“In recognition of the inadequacy of conventional first-line antidepressants and the unmet needs of individuals with TRD, along with the recent US Food and Drug Administration and European Medicines Agency approval of esketamine [8], * Roger S. McIntyre roger.mcintyre@uhn.ca Extended author information available on the…”
BackgroundInfluentialBDNF downregulates 5-HT2A receptor protein levels in hippocampal cultures
Trajkovska, V., Santini, M. A., Marcussen, A. B., Thomsen, M. S., Hansen, H. H., Mikkelsen, J. D., Arneberg, L., Kokaia, M., Knudsen, G. M., & Aznar, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.06.013 · Cited by 32 · cited 1×
“The preceding result suggests possible downstream expression of BDNF following the binding of psilocybin, ultimately leading to downregulation of 5-HT2ARs [59].”
BackgroundNkadimeng, S. M., Steinmann, C. M. L., & Eloff, J. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-79328-5 · Cited by 32 · cited 1×
“, which investigated properties of the comorbidity of heart failure and MDD, demonstrated decreased damage to cardiomyocytes by TNF-α upon administration of psilocybin [78].”
BackgroundReturn of the psychedelics: Psilocybin for treatment resistant depression
Patra, S. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.010 · Cited by 31 · cited 3×
“post-psilocybin administration, multiple studies have demonstrated attenuated right amygdala responses to negative stimuli and associated induction of positive affective states [25, 26].”
BackgroundAyahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?
Malcolm, B. J., & Lee, K. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.01.039 · Cited by 28
Serafini, G., Amore, M., & Rihmer, Z. (2015) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.157955 · Cited by 26
Tanabe, K., Matsushima‐Nishiwaki, R., Dohi, S., & Kozawa, O. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.014 · Cited by 13
Patacchini, A., & Cosci, F. (2021) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-200074 · Cited by 12
Marek, G. J., & Salek, A. A. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264069 · Cited by 10 · cited 1×
“Similarly, administration of DOI in the presence of LY354740 was not able to restore head-twitch behavior in mice whereas administration of DOI with the mGlu2/3 antagonist LY341495 increased head-twitch behavior [85, 86].”
BackgroundPeripheral Inflammatory Biomarkers Define Biotypes of Bipolar Depression
Lee, Y. L., Mansur, R. B., Brietzke, E. M., Kapogiannis, D., Delgado‐Peraza, F., Boutilier, J. J., Chan, T. C. Y., Carmona, N. E., Rosenblat, J. D., Lee, J., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.02.401 · Cited by 5
Self-citation
Cited by
Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study
Peck, S. K., Shao, S., Gruen, T., Yang, K. H., Babakanian, A., Trim, J., Finn, D. M., & Kaye, W. H. (2023) · Nature Medicine · doi:10.1038/s41591-023-02455-9 · Cited by 184
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Self-citationTherapeutic use of psilocybin: Practical considerations for dosing and administration
MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040217 · Cited by 102
“5-HT2A receptors are also highly expressed in the visual cortex, contributing to the visual hallucinations associated with psilocin (27, 32).”
BackgroundEfficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 120
Metadata
- Authors
- Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., Lin, K., Ho, R., Rosenblat, J. D., Castle, D., & McIntyre, R. S.
- Affiliations
- University Health Network (CA)
- Guangzhou Medical University (CN)
- National University of Singapore (SG)
- Centre for Addiction and Mental Health (CA)
- Corresponding author
- McIntyre, Roger S.
- ORCID
- Venue
- CNS Drugs
- Published
- 2021-11-17
- Volume
- 36
- Issue
- 1
- Pages
- 17-30
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W3213007658
- Cited by
- 127
- References
- 134
- Citations by year
- 2026: 25 · 2025: 30 · 2024: 28 · 2023: 34 · 2022: 10
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psilocybin, depression, rapid-acting antidepressants, treatment-resistant depression, 5-HT2A receptor, serotonergic system, ketamine, esketamine, default mode network, amygdala, dopaminergic system, glutamatergic system, gene expression, receptor pharmacology
- MeSH terms
- Antidepressive Agents, Brain, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psilocybin, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.